Perioperative apalutamide plus ADT presents a new option for high‐risk localized prostate cancer
T he combination of perioperative apalutamide with androgen deprivation therapy (ADT) significantly improved pathologic complete response (pCR)/minimal residual disease (MRD) and metastasis-free survival (MFS) in patients with high-risk localized or locally advanced prostate cancer according to results of the PROTEUS trial.Mary-Ellen Taplin, MD, a professor of medicine at Harvard Medical School in Boston, Massachusetts, presented the results of PROTEUS at the
Authors
- Leah Lawrence
Publication Details
- Journal
- Cancer
- Published
- 2026-11-14
- DOI
- https://doi.org/10.1002/cncr.70637
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00